An epigenomic approach to therapy for tamoxifen-resistant breast cancer - Wikidata - awgldk - TriplyDB

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

http://www.wikidata.org/entity/Q33859350

about

Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery Targeting BET bromodomains for cancer treatment 3CPET: finding co-factor complexes from ChIA-PET data using a hierarchical Dirichlet process BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.Tamoxifen for induction of Cre-recombination may confound fibrosis studies in female mice.The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.BETs abet Tam-R in ER-positive breast cancer.HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription.miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.DGCA: A comprehensive R package for Differential Gene Correlation Analysis.The changing role of ER in endocrine resistance.Analysis of factors affecting endocrine therapy resistance in breast cancer.Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains High level of BRD4 promotes non-small cell lung cancer progression.Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.Epigenetics in cancer stem cells.Targeting BET bromodomain proteins in solid tumors JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.AR Signaling in Breast Cancer.BET inhibitors: a novel epigenetic approach.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.Bromodomain inhibitors and cancer therapy: From structures to applications.BET Bromodomain Proteins as Cancer Therapeutic Targets.

P2860

Q27701027-031B3C88-1839-4F03-943A-3CD065514A5E Q28085062-10D07CA3-29BE-4C50-964C-70D7D11C5313 Q28260105-4EF6055C-2C09-4BC3-A7FF-C57C4037534B Q28263519-130B55E4-0C5E-4414-8D97-365AF99CE36F Q31033467-472CCF73-95E1-4435-B10B-207783266C29 Q33557475-840E40C9-A62A-4AD3-822A-63B9C78A8CC5 Q33704579-745E754A-EBB1-400F-A8F2-DCB53CF99362 Q33714763-40BA7727-EFB8-4829-8607-B9A3815646A6 Q33844624-BC7895D2-B640-4109-AECC-80E0DD3ADEE4 Q34008469-F4159B8A-1FA4-4E4B-B803-287361DEC0F7 Q34511826-FA934BE1-5FD5-4983-A65E-4D5168F78112 Q35273689-D1A08053-DC9F-4C66-AAA5-2A184CD3FF77 Q35596991-9D04E397-7E7A-4833-8C85-0C132E04FB7C Q35740207-3249DC64-3F9A-42AB-AE44-FC9164ABF20E Q35932634-F18F6ED3-5322-480F-AE44-94E8B97D118D Q36029524-432ED601-43AE-4A8B-A2A9-05AFA504944A Q36089048-D7E66800-A7F9-423D-82BE-42FCA0FBFDA7 Q36185007-22E241BC-C678-48A8-A91D-B2EC77182C21 Q36193416-0CB6C8A4-7FBC-4A80-86D1-1FC05EF5D58B Q36336601-0DB295C4-3501-46D6-831B-F14465D14DE6 Q36502389-735954BB-2959-4942-A5E9-F7C73E7B8E6B Q36559908-FDFB401A-E68E-4246-A54F-8816DFB89AB7 Q36962647-080C7624-CD7C-4C2C-8E58-D67D178C0A2F Q37031949-F1B7E367-C15D-4691-A839-16414E0273AF Q37200775-7CD15D3E-ADFA-4306-BED3-D6E449E97E32 Q37240015-90EF2E04-C009-4C16-B074-0B72C33F987D Q37333948-EC6293C5-B0E0-46F0-BB10-E3D3506491EF Q37618640-290EF9EA-A9BD-4E67-8932-28BFE61B9745 Q37619860-E158C367-E302-4225-9082-093890D1B45B Q37687075-B3384479-A22B-4FB4-B3CB-5E6619EED540 Q37688020-4E018E07-C5F6-45A7-82CF-D503884FE9B7 Q37688408-431902E9-4CDF-441E-BA28-E14B3E65031F Q37721492-C5B01DCD-14D5-448E-B3C6-1697468D390B Q38609772-B7AAC715-5D1E-45C0-9A1D-B71D78544B7C Q38741165-78AA64F0-1874-4ACE-A2AC-E8F16CDBBB9F Q38744664-89EB4C09-1A04-4A3A-9F7F-A043911AEC1A Q38850598-0530F2C8-CF59-45E7-8574-F034EC4031F0 Q38895410-E2AB3E9D-FCF7-4337-BEA2-9922570FA8D8 Q39027056-D151ACF2-F92F-4AEB-97C6-DC799374E476 Q39071349-2471973C-3357-44C8-8FC9-4CA8F649B2DD

P2860

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

http://www.wikidata.org/entity/Q33859350

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@ast

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@en

type

label

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@ast

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@en

prefLabel

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@ast

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@en

P1433

Q33859350-A8B0649C-CC6E-4EE1-806F-7CF67FD0E1C9

P1476

Q33859350-2420CF41-340F-4EF4-A407-3A6B3F91FA6F

P2093

Q33859350-0762599E-8C82-4F2E-87A5-6A4B67723A99

Q33859350-15AE83BD-A7BF-43AB-8C49-81FE8B225A0A

Q33859350-1B0BD551-B48C-4952-B46B-915D790CC508

Q33859350-20024B26-D668-4FDF-8672-1F63B855CEB4

Q33859350-20F16B00-9E79-42D2-B9BD-0BD15FFF4155

Q33859350-217F8A0D-20C8-416C-8545-C04C17C8755D

Q33859350-23FEB265-4C4B-4477-ADD5-84FF2FCFB609

Q33859350-39F6FD61-6320-48D6-9C12-0BE69035239A

Q33859350-467AD7A3-81A5-461B-827E-3C06A2A1176E

Q33859350-4B97BF19-6F2C-4EB7-977A-DF5D3CB118EF

P2860

Q33859350-00040F58-43B8-44FA-81B1-C8DBF1755B34

Q33859350-0252A505-2BCF-44D3-94B8-3D7CC89813FC

Q33859350-040DE219-EA61-41F6-8F7F-B04639586D50

Q33859350-04C11083-BF9E-4865-A5FB-92DD3753FC32

Q33859350-05BFF7D6-4496-4D9E-BEBB-777B1B56E4DE

Q33859350-0711AF6A-3C6C-4BD4-AB7A-FB6BEF4E6BB3

Q33859350-0F9C847E-5163-4D1B-85B5-1E9A3C466627

Q33859350-12540457-6A2D-48D4-89E2-8DF8051F165A

Q33859350-1FAA4141-4A07-4311-89D9-C69A7701FD08

Q33859350-1FF68BB6-2F0A-4FEB-82AD-1640832FB2B8

P2888

Q33859350-267E9F58-A807-4FAB-91B9-E8B2A94C5AA2

P304

Q33859350-1B801FE2-70F2-4496-9EF2-97B73C75C2C4

P31

Q33859350-42BBFDD2-2AC0-474B-B23C-CDDCDB8986C8

P356

Q33859350-A5032965-B437-4E14-8B37-1D0F42390C2A

P433

Q33859350-AF9BCFCF-6EFB-4174-8F84-24FC78CB88EE

P478

Q33859350-632B6B92-A400-485D-A38B-7E054A7300D7

P50

Q33859350-389AB27D-401D-40E7-8319-674E6950903C

P577

Q33859350-7B433267-473F-4CF7-924A-A87E69B4AAA8

P5875

Q33859350-4858EE04-C436-4736-94CC-10640A204126

P698

Q33859350-48C6975F-710F-4C90-8A41-28B22844DDD4

P932

Q33859350-47874DBA-E7D0-468A-BC8E-9F707E680FDE

P356

P1433

P1476

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

@en

P2093

Agostina Nardone

http://www.w3.org/2001/XMLSchema#string

Bin He

http://www.w3.org/2001/XMLSchema#string

C Kent Osborne

http://www.w3.org/2001/XMLSchema#string

Chad J Creighton

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Cristian Coarfa

http://www.w3.org/2001/XMLSchema#string

James Bradner

http://www.w3.org/2001/XMLSchema#string

Lei Wang

http://www.w3.org/2001/XMLSchema#string

Martin J Shea

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

P2860

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

Comprehensive molecular portraits of human breast tumours

Epigenetics in breast cancer: what's new?

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Integrated genomic analyses of ovarian carcinoma

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis

The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome

P2888

P304

809-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CR.2014.71

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Bert W. O'Malley

P577

2014-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262787466

http://www.w3.org/2001/XMLSchema#string

P698

24874954

http://www.w3.org/2001/XMLSchema#string

P932

4085766

http://www.w3.org/2001/XMLSchema#string